- Home
- |
- About
- |
- Products
- |
- News and Media
- |
- Investors
- |
- Online Pharmacy
- |
- Contact Us
MC-1 is an investigational drug that contains pyridoxal 5'-phosphate monohydrate (PLP), a naturally occurring metabolite of pyridoxine (vitamin B6). Medicure Pharma is currently evaluating the safety and efficacy of MC-1 to treat patients with pyridox (am) ine 5'-phosphate oxidase (PNPO) deficiency.
Pyridox (am) ine 5'-phosphate oxidase (PNPO) deficiency is an inborn error of vitamin B6 metabolism, which causes an epileptic encephalopathy responsive to pyridoxal-5-phosphate (PLP). This deficiency is caused by mutations in the PNPO gene encoding this enzyme. Intractable neonatal epileptic encephalopathy within the first hours of life is the classical presentation of PNPO deficiency. Intractable neonatal epileptic encephalopathy is characterized by the onset, shortly after birth, of drug-resistant seizures associated with severe neurological dysfunction.
Medicure Pharma has received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA) for MC-1 for the treatment of PNPO deficiency.
Medicure is conducting a Phase 3, prospective, open-label, multi-center study to assess the safety and efficacy of MC-1 in patients with confirmed PNPO deficiency via genetic analysis (MEND-PNPO). For more information about this study, please visit clinicaltrials.gov
Pat Follows
Project Manager
Telephone: 204-594-3410
Email: pfollows@medicure.com
Recent NewsMedicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency |
Clinical Trials: MC-1Medicure is conducting the MEND-PNPO study, a Phase 3 study to assess the safety and efficacy of MC-1 in patients with confirmed PNPO deficiency via genetic analysis. |
Tardive DyskinesiaMedicure has filed an FDA IND and conducted a 12-week, randomized, double-blind, placebo-controlled, parallel group comparative study to evaluate the safety and efficacy of TARDOXAL in the treatment of tardive dyskinesia. |
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts
Copyright © 2023 Medicure Inc. All Rights Reserved. | Privacy Statement